ABSTRACT

Aberrant DNA methylation is associated with cancer development and progression. There are several types of specimens from which DNA methylation pattern can be measured and evaluated as an indicator of disease status (from normal biological process to pathologic condition) and even of pharmacologic response to therapy. Blood-based specimens such as cell-free circulating nucleic acid and DNA extracted from leukocytes in peripheral blood may be a potential source of noninvasive cancer biomarkers. In this article, we describe the characteristics of blood-based DNA methylation from different biological sources, detection methods, and the factors affecting DNA methylation. We provide a comprehensive literature review of blood-based DNA methylation as a cancer biomarker and focus on the study of DNA methylation using peripheral blood leukocytes. Although DNA methylation patterns measured in peripheral blood have great potential to be useful and informative biomarkers of cancer risk and prognosis, large systematic and unbiased prospective studies that consider biological plausibility and data analysis issues will be needed in order to develop a clinically feasible blood-based assay.

Key words: DNA methylation; blood-based biomarker; serum; plasma; leukocyte; peripheral blood

1. INTRODUCTION

Biomarkers are biological molecules in body fluids or tissues that are quantitatively measured and evaluated as indicators of normal biological processes, pathogenesis, or pharmacologic response to a therapeutic intervention. Numerous types of biomarkers have been developed and used for early detection of cancer and prediction of prognosis and treatment response in cancer patients.

DNA methylation is a main component of the epigenetic mechanism that regulates embryonic development, transcription, chromatin structure, X-chromosome inactivation, genomic imprinting, and chromosome stability. DNA methylation occurs at the 5-carbon position of cytosine residues located in dinucleotide CpG sites. Although CpG within intergenic and transposable elements throughout the whole genome are mostly methylated, most CpG islands at the promoter region are unmethylated. In cancer, global loss of DNA methylation (global hypomethylation), as well as hypermethylation and hypomethylation of specific loci, has been observed. It has been suggested that altered DNA methylation initiates carcinogenesis and promotes cancer progression by activating oncogenes, suppressing tumor suppressor genes, and inducing chromosome instabilities.

Because DNA is much more stable than other biological materials, such as RNA or protein, DNA methylation is easy to detect in small specimens and thus may be suitable for large-scale epidemiologic studies. Previous studies of the potential of DNA methylation as a cancer biomarker mainly used tumor tissue. However, an increasing number of studies...
are using body fluids such as urine, bronchial lavage fluid, breast milk, sputum, plasma and serum, and peripheral blood.5

In this review, we consider only studies that analyzed cell-free circulating DNA in plasma or serum or DNA from peripheral blood leukocytes. We describe the characteristics of blood-based DNA methylation from different biological sources, detection methods, and factors affecting DNA methylation. In addition, we comprehensively review the literature to investigate blood-based DNA methylation as a cancer biomarker, with a focus on studies using peripheral blood leukocytes.

2. ISSUES IN THE DEVELOPMENT OF METHYLATION-BASED BIOMARKERS USING PERIPHERAL BLOOD

2.1 Characteristics of different sources of blood-based DNA methylation

Blood-based DNA methylation is mainly derived from cell-free nucleic acid released from circulating cells in serum or plasma6 or DNA extracted from peripheral blood leukocytes or whole blood cells. Although cell-free DNA from circulating cells can serve as a surrogate for DNA from target tumor tissue, it is mixed with DNA from normal cells, which results in low specificity. In addition, the amount of DNA from serum or plasma is somewhat limited for use as a biomarker.7 However, a pooling method that uses DNA from groups of individuals has shown promise in identifying significant methylation markers.8

In contrast, the amount and quality of DNA extracted from peripheral blood leukocytes or whole blood are not usually a concern. Furthermore, it is common practice in many biospecimen repositories to bank DNA extracted from blood leukocytes. Although DNA from peripheral leukocytes is readily obtainable and easy to handle in laboratory processing and clinical use, the biological plausibility of DNA methylation in peripheral blood leukocytes and whole blood is uncertain.

Global methylation in peripheral blood leukocytes significantly differed between healthy controls and patients with pancreatic cancer, breast cancer, bilateral breast cancer, bladder cancer, and colorectal adenoma.9–13 Although methylation at specific loci in leukocytes was also observed in people with colorectal tumors, the correlation with target tissue showed little evidence of the origin of leukocyte methylation.14 Similarly ambiguous results were reported with regard to the correlation between methylation at specific loci in peripheral blood leukocytes/whole blood DNA and lung tissue DNA.15 Thus, it is controversial as to whether DNA methylation from peripheral blood leukocytes reflects methylation of target tissue.

It has been suggested that immunologic processes related to inflammation in cancer development lead to changes in leukocyte subpopulations, which could alter the epigenetic signatures in DNA from peripheral blood.16 Another possible explanation is that epigenetic change due to methylation is associated with the genetic variants of specific cancers.16,17 Increased knowledge of the origin and nature of DNA methylation in peripheral blood leukocytes is needed to determine whether DNA methylation in such cells can serve as an informative biomarker. In addition, future studies should investigate variation in DNA methylation in heterogeneous leukocyte subpopulations and differences in the processing of white blood cells.

2.2 Detection methods

To identify a sensitive and specific biomarker, it is important to select an appropriate method that is standardized, robust, sensitive, and cross-validated between laboratories and across different platforms. The details of such methods have been comprehensively reviewed in several articles4,18–21 We will describe the advantages and disadvantages of extant methods of DNA methylation and will focus on the methods frequently used to detect DNA methylation in peripheral blood. Table 1 summarizes the methods used to assess DNA methylation and several of the important factors to be considered in method selection, such as analytical sensitivity measured as limit of detection (LOD), quantitiveness, and time required.

| Candidate gene | LOD a | Quantitativeness | Time requirement | Reference |
|----------------|-------|------------------|------------------|-----------|
| MSP            | 0.1   | No               | <2 hrs/96        | 74        |
| Bisulfite sequencing | >2   | Yes              | >4 hrs/96        | 75        |
| Pyrosequencing  | 2     | Yes              | 4 hrs/96         | 78        |
| COBRA          | 3     | No/Yes           | 5 hrs/80-160     | 77, 78    |
| MS-SnuPE       | 0.1   | Yes              | 5 hrs/80-160     | 79, 80    |
| MethLight      | 0.01  | Yes              | <2 hrs/96        | 81        |
| MS-FLAG        | 0.01  | Yes              | <2 hrs/96        | 82        |

Abbreviations: LOD, limit of detection; MSP, methylation-specific PCR; COBRA, combined bisulfite restriction analysis; MS-SnuPE, methylation-sensitive single-nucleotide primer extension; MS-FLAG, methylation-specific fluorescent ampiclon generation; RLGS, restriction landmark genomic scanning; MeDIP, methyl-DNA immunoprecipitation; MIRA, methylated-CpG island recovery assay; HPLC, high-performance liquid chromatography; HPCE, high-performance capillary electrophoresis; LC-ESI-MS, liquid chromatography–electrospray ionization–mass spectrometry.

aRatio of methylated cytosine to unmethylated cytosine (for the gene-specific methylation approach [%]) or the amount of DNA (for the global DNA methylation approach).

PCR amplification of desired target was conducted after bisulfite conversion.
Methylation at specific loci can be examined in selected candidate genes or genome-wide. Most candidate gene analyses are based on bisulfite treatment and PCR/sequencing followed by quantitative measurement of DNA methylation level. The process of bisulfite treatment and PCR can be done using a relatively small amount of low-quality DNA and is thus suitable for DNA derived from serum or plasma, as well as that from peripheral blood leukocytes. There are 3 types of methods to measure methylation level at specific loci, ie, real-time PCR-based methods (methylation-specific melting curve analysis [MS-MCA], methylation-sensitive high-resolution melting [MS-HRM], HeavyMethyl, MethylLight), melting curve methylation-specific PCR [McMSP], sensitive melting analysis after real-time methylation-specific PCR [SMART-MSP], methylation-specific fluorescent amplicon generation [MS-FLAG], and quantitative analysis of methylated alleles [QAMA]); sequencing-based methods (direct bisulfite sequencing and pyrosequencing); and gel electrophoresis-based methods (combined bisulfite restriction analysis [COBRA] and methylation-sensitive single-nucleotide primer extension [MS-SnuPE]).

Methyl-sensitive enzyme digestion, affinity enrichment, and the bisulfite treatment-based array are used for genome-wide profiling. There are a variety of enzyme digestion methods such as restriction landmark genomic scanning (RLGS), methylation-sensitive restriction fingerprinting (MSRF), differential methylation hybridization (DMH), and methylated CpG island amplification/representational difference analysis (MCA-RDA). However, enzyme digestion methods generally require a large amount of DNA (approximately 10 µg) and have limited coverage for DNA as compared with affinity enrichment methods (methylation-CpG island recovery assay [MIRA], methyl-DNA immuno-precipitation [MeDIP], tiling array, CpG island microarray, and next-generation sequencing [NGS]) or a bisulfite treatment-based array.20 Neither enzyme digestion methods nor affinity enrichment methods can focus on specific CpG sites of interest, and thus the results are likely to be biased toward CpG-dense regions, due to the different efficiency of enzyme digestion and changes in antibody efficiency through different runs. In contrast, the bisulfite treatment-based array combined with bead array technology, such as the Infinium methylation array, requires only a small amount of DNA (250–500 ng) and is highly reproducible ($r^2 > 0.998$).10 The correlation coefficients of the Infinium and GoldenGate assays, pyrosequencing, and bisulfite sequencing were reported to be greater than 0.8.22 Methods for genome-wide profiling can be classified as array-based analysis and deep sequencing, according to genotyping technology. Bock et al11 compared the different platforms of 4 types of genome-wide DNA methylation-mapping technologies, including methylated DNA immunoprecipitation sequencing (MeDIP-seq), methylated DNA capture by affinity purification sequencing (MethylCap-seq), reduced representation bisulfite sequencing (RRBS), and the Infinum methylation assay. They reported that the accuracy of the RRBS and Infinum assays was slightly higher than that of the other 2 methods. However, the genomic coverage of MeDIP-seq and MethylCap-seq was higher than that of the RRBS and Infinum assays.

Global DNA methylation can be measured by direct and indirect quantification assays. Direct methods, such as the [$^{3}H$]-methyl incorporation assay, high-performance liquid chromatography (HPLC), high-performance capillary electrophoresis (HPCE), and liquid chromatography-electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS), measure 5-methylcytosine content throughout the genome. LC-based methods are the most common and have good reproducibility. LC-ESI-MS/MS needs less DNA than the other methods (1 µg for LC-ESI-MS/MS vs 5–10 µg for HPLC) and requires less time per sample (15–60 min for separation using HPLC vs <15 min for separation using LC-ESI-MS/MS).23,24 Direct measurement of 5-methylcytosine content in DNA requires a large amount of DNA and is labor intensive, which led to the development of an indirect method that measures methylation levels of repetitive elements (ALU, LINE1, and SAT). The repetitive elements represent over 45% of CpG dinucleotides in the human genome and are correlated with 5-methylcytosine levels throughout the genome.25 Using MethylLight, Weisenberger et al reported that the methylation level of repeated elements was correlated with global DNA methylation as measured by HPLC.25 However, it is uncertain whether methylation levels of repetitive elements perfectly represent 5-methylcytosine content.

### 2.3 Factors affecting DNA methylation

A valid biomarker should have greater interindividual than intra-individual variation and higher interclass than intraclass correlation coefficients. Several studies have shown that DNA methylation pattern changed over time according to various endogenous and exogenous factors, such as demographic and lifestyle factors (age, race, sex, smoking, and alcohol consumption), diet intake (folate, vitamin B, green tea, and phytoestrogen), environmental exposures (arsenic, cadmium, and benzene), and disease status (infection and cancer).26

The methylation levels of several genes were shown to be correlated with smoking, alcohol consumption, and high-fat intake, although most studies using cell-free DNA in serum and/or plasma did not show any significant association.27–29 Interestingly, several well-designed epidemiology studies found that obesity, dietary pattern, and physical activity were associated with global methylation in DNA extracted from peripheral blood leukocytes. Recently Teschendorff et al10 conducted a genome-wide scan of 27,000 CpG sites in 261 postmenopausal women and found that most CpGs were hypermethylated with age. Breitling et al11 used the same approach and found that specific methylation of F2RL3 was associated with tobacco smoking in 177 individuals.
and validated this result using mass spectrometry and the Sequenom EpiTYPER in 316 individuals. In addition, a very recent review \cite{32} showed that demographic factors (age, sex, race, family history of cancer, education and race), environmental factors (benzene, organic pollutants, lead, arsenic, air pollution), behavioral factors (smoking, alcohol drinking, physical activity, and folate intake), and even genetic variation in carbon-metabolizing enzymes were associated with global methylation level in lymphocyte DNA. \cite{9,33-38} Thus, potential confounding factors affecting methylation status should be considered in the design of studies evaluating DNA methylation as a cancer biomarker. Furthermore, findings in the discovery stage should be cross-validated using independent samples.

3. PREVIOUS STUDIES OF DNA METHYLATION IN PERIPHERAL BLOOD AS A BIOMARKER OF CANCER RISK AND PROGNOSIS

We searched MEDLINE (PubMed) using the following keywords: DNA methylation, cell in serum and/or plasma, peripheral blood leukocytes, and cancer. We also searched the references of the retrieved articles. Among the identified studies, we included only those that had an epidemiologic design (cohort study, case-control study, or case-only study) and investigated DNA methylation as a biomarker of cancer risk and prognosis.

3.1 Circulating cell-free DNA methylation as a cancer biomarker

Table 2 shows the studies that used circulating cell-free DNA in serum and/or plasma to investigate DNA methylation as a diagnostic biomarker of cancer. In studies using circulating nucleic acid, the candidate gene approach was more frequent than genome-wide analysis, possibly due to the limited amount of available DNA. Previous studies have focused on genes and pathways related to carcinogenesis and tumor progression, namely, tumor oncogenes (TMEFF2, HPP1, and PGR), tumor suppressor genes (TIG1, APC, RASSF1A, and DAPK), cell cycle-related genes (P16(INK4a), 14-3-3δ, GSTP1, p15, p16, RAR-β, and SEPT9), cell adhesion molecules (CDH1 and CDH13), cell proliferation-related genes (ESR1, MYOD, and PTGS2), tissue invasion- and metastasis-related genes (TIMP3 and E-cadherin), and others (hMLH1, NGFR, AR, MGMT, HLF, and TPEE). As compared with healthy individuals, DNA methylation of the tumor suppressor genes APC and RASSF1A was altered in circulating cell-free DNA of patients with breast or gastric cancer. \cite{39-42} DNA methylation of cell cycle-related genes such as P16(INK4a), 14-3-3δ, GSTP1, p15, p16, RAR-β, and SEPT9 was reported in bladder, lung, prostate, and colorectal cancer and in head and neck squamous cell carcinoma. \cite{43-48} However, almost all these studies failed to adjust for confounding factors, including well-known cancer risk factors. Only 1 study showing promoter hypermethylation in MGMT, P16(INK4a), RASSF1A, DAPK, and RAR-β in lung cancer patients reported risk estimates adjusted for age, sex, smoking status, and protein tumor marker. \cite{47} Recently, Epigenomics AG \cite{49} conducted a multistage study to identify and validate methylation biomarkers for colorectal cancer. In the first stage, candidate markers were selected by restriction enzyme-based discovery methods using colorectal cancer tissue and normal tissue. In the second stage, candidate genes identified in the first stage (i.e., TMEFF2, NGFR, and SEPT9) were confirmed by real-time assays using DNA from circulating plasma cells. \cite{48} Finally, SEPT9 methylation identified in the second stage was validated in a clinical trial.

Several studies have evaluated the potential of DNA methylation as a prognostic biomarker of cancer. Table 3 summarizes studies that investigated DNA methylation in circulating cell-free DNA as a prognostic biomarker. In a variety of cancers, including hepatocellular carcinoma, breast, bladder, cervical, and colorectal cancer, \cite{50-54} both the methylation pattern in specific loci and global methylation level were observed with regard to disease-free survival and/or overall survival. Altered DNA methylation of APC was commonly associated with overall survival in breast, gastric, and esophageal cancer. \cite{28,55-57} Promoter methylation of cell adhesion molecule genes CDH1 and CDH13 and cell proliferation-related gene MYOD was associated with relapse-free survival in cervical cancer. \cite{53,58} Promoter methylation of GSTP1 was associated with disease-free survival in prostate cancer, and hMLH1 was associated with overall survival in ovarian cancer. \cite{59,60} In hepatocellular carcinoma, global hypomethylation quantified with LINE1 was associated with overall survival. \cite{29} A few studies shown in Table 4 evaluated the predictive values, including sensitivity and specificity, of DNA methylation in predicting cancer outcomes. In colorectal cancer and prostate cancer, multimarker analysis had much higher sensitivity and specificity than did single-marker analysis. \cite{51,62} Moreover, in some cases, the sensitivity and specificity of methylation markers were reported to be moderately higher than those of present diagnostic markers in clinical use, such as PSA for prostate cancer, fecal occult blood testing for colorectal cancer, CA125 for ovarian cancer, and combined analysis of CA19-9 and CA125 for pancreatic cancer.

3.2 Leukocyte DNA methylation as a cancer biomarker

Table 5 shows the associations between methylation patterns of DNA extracted from leukocytes and cancer risk. Methylation at specific loci in DNA from peripheral blood leukocytes/whole blood was first reported in lung cancer. \cite{55} In a nested case-control study (n = 100), the researchers hypothesized that methylation status in DNA extracted from whole blood would reflect the status of lung tissue DNA. They identified a correlation between p53 gene hypomethylation...
in whole blood DNA and lung cancer. In breast cancer, methylation of specific loci in ERT (NUP155 and ZNF217), PCGT (TITF1, NEUROD1, and SFRP1), and DMHR (PTGS2) of DNA from extracted peripheral blood cells was associated with breast cancer risk.\(^13\) Flanagan et al\(^10\) compared the methylation pattern of peripheral blood DNA using a custom methylation microarray analysis covering 4 Mb with 51 candidate genes from 14 bilateral breast cancer cases and 14 normal controls and validated their initial findings regarding the tiled region around ATM in 190 pairs of cases and controls. The results proved their hypothesis that some systemic epigenetic changes would be detected in peripheral blood DNA in breast cancer. However, in a case-control study using lymphocyte DNA from 97 colon cancer cases and 190 age- and sex-matched controls, the mean fraction of CpG methylation was identical among cases and controls, and there was no relationship between colon cancer risk and quartile levels of CpG methylation.\(^63\)

In genome-wide scanning using leukocyte DNA, potential methylation biomarkers were identified in several cancers,

### Table 2. Associations between serum and/or plasma DNA methylation and cancer risk

| Genes              | Sample size (cases/controls) | Assay       | Source       | OR (95% CI), P   | Reference |
|--------------------|------------------------------|-------------|--------------|-----------------|-----------|
| **Breast cancer**  |                              |             |              |                 |           |
| RASSF1A            | 33/29                        | MSP         | Plasma       | Case: 12%; Control: 0% | 40        |
| APC                | 79/19                        | QMSP        | Serum        | APC: P = 0.03    | 39        |
| ESR1               |                              |             |              | ESR1: P = 0.33   |           |
| RASSF1A            |                              |             |              | RASSF1A: P = 0.002| 88        |
| APC                | 36/30                        | EpiTyper assay | Plasmas/Serum | APC: P < 0.001  |           |
| BMP6               |                              |             |              | BIM1: P < 0.001  |           |
| BRCA1              |                              |             |              | BMP6: P = 0.068  |           |
| CST6               |                              |             |              | BRCA1: P < 0.001 |           |
| ESR-b              |                              |             |              | CST6: P < 0.002  |           |
| GSTP1              |                              |             |              | ESR-b: P = 0.122 |           |
| P16                |                              |             |              | GSTP1: P = 0.003 |           |
| P21                |                              |             |              | P16: P < 0.001   |           |
| TIMP3              |                              |             |              | P21: P < 0.0001  |           |
| **Bladder cancer** | **P16\(^{\alpha k_a}\)**   | 86/49       | MSP          | Serum            | 13.6 (1.8–105.2), P = 0.0009 | 43        |
| **Gastric cancer** | RASSF1A                      | 47/30       | MSP          | Serum            | P < 0.01  | 41        |
| APC                | 60/22                        | MethyLight  | Serum        | APC: P = 0.08    | 56        |
| hMLH1              |                              |             |              | hMLH1: P = 0.03  |           |
| TIMP3              |                              |             |              | TIMP3: P = 0.005 |           |
| **Head and neck squamous cell carcinoma** | p15 | 20/24 | MethyLight | Plasma | p15: P = 0.0037 | 46        |
| p16                |                              |             |              | p16: P = 0.016   |           |
| **Lung cancer**    | DAPK                         | 100/100     | MSP          | Serum            | At least 1 gene positive: 5.3 (2.4–11.7) | 47        |
| MGMT               |                              |             |              | At least 2 genes positive: 5.9 (1.5–22.7) |           |
| P16\(^{\alpha k_a}\) | RASSF1A                      |             |              |                  |           |
| **Nasopharyngeal carcinoma** | CDH1 | 41/43 | QMSP | Plasma | CDH1: P < 0.0001 | 89        |
| DAPK               |                              |             |              | DAPK: P = 0.002  |           |
| p15                |                              |             |              | p15: P = 0.002   |           |
| p16                |                              |             |              | p16: P < 0.0001  |           |
| RASSF1A            |                              |             |              | RASSF1A: P = 0.235 | At least 1 gene positive: P < 0.001 |           |
| **Prostate cancer** | GSTP1                        | 168/11      | QMSP         | Serum            | GSTP1: P < 0.0001 | 45        |
| PTGS2              |                              |             |              | PTGS2: P = 0.05  |           |
| TIG1               | 46/49                        | MSP         | Serum        | TIG1: P = 0.038  |           |
| 14-3-3\(\alpha\)  |                              |             |              | 14-3-3\(\alpha\): P = 0.03 | 44        |
| AR                 |                              |             |              | AR: P > 0.05    |           |
| GSTP1              |                              |             |              | GSTP1: P < 0.001 |           |

Abbreviations: MSP, methylation-specific PCR; QMSP, quantitative methylation-specific PCR; MSRE, methylation-sensitive restriction enzyme; HPCE, high-performance capillary electrophoresis; LC/MS, liquid chromatography/mass spectrometry; COBRA, combined bisulfite restriction analysis.

\(^a\)Hypermethylation of genes increased cancer risk.
Table 3. Associations between serum and/or plasma DNA methylation and cancer prognosis

| Genes | Sample size (events/non-events) | Assay | Outcome | HR (95% CI), P | Reference |
|-------|---------------------------------|-------|---------|---------------|----------|
| **Breast cancer** | | | | | |
| RASSF1A | 13/148 | MethyLight | Relapse-free survival | 5.1 (1.3–19.8) | 55 |
| APC | 17/85 | MethyLight | Overall survival | 5.7 (1.9–16.9), P = 0.002 | 28 |
| PITX2 | 428 | MethyLight | Overall survival | 5.1 (1.3–19.8), P = 0.002 | 51 |
| RASSF1A | | | Distant disease-free survival | | |
| **Bladder cancer** | | | | | |
| P14ARF | 12/15 | MSP | Relapse-free survival | 5.1 (1.3–19.8), P = 0.002 | 52 |
| **Cervical cancer** | | | | | |
| MYOD1 | 53/40 | MethyLight | Relapse-free survival | 5.1 (1.3–19.8), P = 0.002 | 58 |
| CDH1 | 53/40 | MethyLight | Relapse-free survival | 5.1 (1.3–19.8), P = 0.002 | 53 |
| **Colorectal cancer** | | | | | |
| HLTF | 28/77 | MethyLight | Overall survival | 5.1 (1.3–19.8), P = 0.002 | 54 |
| HPP1 | | | Overall survival | 5.1 (1.3–19.8), P = 0.002 | 57 |
| hMLH1 | | | Overall survival | 5.1 (1.3–19.8), P = 0.002 | 57 |
| **Esophageal cancer** | | | | | |
| DAPK | 59 | QMSP | Overall survival | 0.2 (0.0–0.5), P = 0.0036 | 90 |
| APC | 52 | QMSP | Overall survival | 0.2 (0.0–0.5), P = 0.0036 | 90 |
| **Gastric cancer** | | | | | |
| APC | 32/26 | MethyLight | Overall survival | 0.2 (0.0–0.5), P = 0.0036 | 90 |
| CDH1 | | | Overall survival | 0.2 (0.0–0.5), P = 0.0036 | 90 |
| **Hepatocellular carcinoma** | | | | | |
| LINE1 | 85 | COBRA | Overall survival | 0.2 (0.0–0.5), P = 0.0036 | 90 |
| **Lung cancer** | | | | | |
| DAPK | 76 | QMSP | Overall survival | 0.2 (0.0–0.5), P = 0.0036 | 90 |
| 14-3-3 | 75/40 | MSP | Overall survival | 0.2 (0.0–0.5), P = 0.0036 | 90 |
| **Ovarian cancer** | | | | | |
| hMLH1 | 78/53 | MSP | Overall survival | 0.2 (0.0–0.5), P = 0.0036 | 90 |
| **Prostate cancer** | | | | | |
| GSTP1 | 83/40 | MSP | Disease-free survival | 4.4 (2.2–8.8), P < 0.001 | 90 |

Abbreviations: MSP, methylation-specific PCR; QMSP, quantitative methylation-specific PCR; COBRA, combined bisulfite restriction analysis; REQP, restriction endonuclease quantitative PCR.

Table 4. Population validation of methylation-based biomarkers using plasma/serum DNA

| Genes | Sample size (cases/controls) | Assay | Source | Sensitivity (%) | Specificity (%) | Reference |
|-------|-----------------------------|-------|--------|----------------|----------------|----------|
| APC, GSTP1, RASSF1A, RARβ2 | 93/76 | QMSP | Plasma | 62 | 87 | 92 |
| APC, MGMT, RASSF2A, Wif-1, SEPT9 | 243/276 | MSP | Plasma | 87 | 92 | 62 |
| APC, GSTP1, RASSF2A, Wif-1, SEPT9 | 97/172 | MethDet test | Plasma | 87 | 92 | 62 |
| P15, P16, RASSF1A | 50/50 | MSP | Serum | 84 | 94 | 62 |
| BRCA1, HIC1, PAX5, PGR, THBS1 | 33/33 | MethDet test | Plasma | 85 | 61 | 62 |
| CCND2, PLAU, SOCS1, THBS, VHL | 30/30 | MethDet test | Plasma | 76 | 59 | 62 |
| GSTP1, RASSF1, RARB2 | 83/40 | MSP | Serum | 89 | — | 62 |

Abbreviations: QMSP, quantitative methylation-specific PCR; MSP, methylation-specific PCR.
including ovarian, pancreatic, bladder, and non–small-cell lung cancers.16,17,64,65 Teschendorff et al16 evaluated the methylation signature of 27,000 CpG sites using DNA extracted from peripheral blood in 113 pretreatment ovarian cancer cases and 148 healthy controls and validated the results among an independent set of 122 post-treatment ovarian cancer cases. Marsit et al64 used an Infinium methylation chip and identified a panel of DNA methylation loci that might serve as a useful biomarker of bladder cancer. In the first phase, they identified a panel of 9 CpG loci in 112 cases and 118 controls and then validated the findings in 111 cases and 119 controls. In the discovery stage of another genome-wide

### Table 5. Associations between DNA methylation in peripheral blood leukocytes and cancer risk

| Disease/Genes | Sample size (cases/controls) | Assay | Results OR (95%CI) | Reference |
|---------------|-----------------------------|-------|------------------|-----------|
| **Breast cancer** | | | | |
| NEUROD1 | 353/730 | MethyLight | 1.5 (1.1–2.0) | 13 |
| NUP155 | | | 1.4 (1.0–1.9) | |
| SFRP1 | | | 1.4 (1.1–1.9) | |
| TITF1 | | | 1.5 (1.1–2.2) | |
| ZNF217 | | | 1.5 (1.1–2.0) | |
| ATM | 190 /190 | MSRE-microarray, Pyrosequencing | High vs Low: 3.2 (1.8–5.9) | 10 |
| 5-mdC | 176/173 | LC/MS | Middle vs High: 1.5 (0.8–2.7) | 9 |
| LINE1 | 40/40 | MethyLight | Low vs High: 2.9 (1.7–4.9) | 95 |
| ALU SAT | | | P > 0.05 | |
| **Bladder cancer** | mC contentsa | | | 11 |
| LINE1 | 775/397 | HPCE | Q1 vs Q4: 2.7 (1.8–4.0) | |
| Gene panels | (9 CpG sites) | | Q2 vs Q4: 1.6 (1.1–2.4) | |
| LINE1 | 510/528 | Pyrosequencing | Q3 vs Q4: 2.1 (1.4–3.1) | |
| Colon cancer | IGFl | 111/119 | Illumina Infinium beadchip array | 64 |
| LINE1 | 285/465 | Pyrosequencing | AUC: 0.8 (0.7–0.8) | |
| **Colon cancer** | mC contents | 115/115 | LC/MS | 12 |
| ALU LINE1 | 302/421 | Pyrosequencing | Low vs High: 1.3 (0.9–1.9) | |
| **Hereditary diffuse gastric cancer** | CDH1 | 22/21 | Pyrosequencing | 97 |
| **Head and neck squamous cell carcinoma** | LRE1 | 278/526 | COBRA | 34 |
| **Lung cancer** | P53 | 100/100 | HpaII quantitative PCR assay | 15 |
| CSF3R | 138/138 | Illumina beadchip assay, pyrosequencing | 2.2 (1.0–4.7) | |
| ERCC1 | | | 3.9 (2.0–6.1) | |
| **Ovarian cancer** | Gene panels | 255/148 | Illumina Infinium beadchip array | 16 |
| (100 CpG sites) | | | AUC: 0.8 (0.7–0.9) | |
| **Pancreatic cancer** | IL10 LCN2 ZAP70 AIM2 TAL1 | 220/220 | Illumina VeraCode array | 17 |

Abbreviations: MSRE, methylation-sensitive restriction enzyme; HPCE, high-performance capillary electrophoresis; 5-mdC, 5-methyldeoxycytosine; LC/MS, liquid chromatography/mass spectrometry; AUC, area under the curve; COBRA, combined bisulfite restriction analysis.
scanning study, CSF3R and ERCC1 gene methylation was identified as a biomarker of small-cell lung cancer using a methylation array of 1505 CpG sites in 39 small-cell lung cancer cases and 44 matched controls, which was validated in an independent set of 138 matched case-control pairs using pyrosequencing.65 Pedersen et al17 conducted a 2-phase study using the GoldenGate methylation Beadchip for phase I and the Illumina custom VeraCode methylation assay for phase II in 220 pairs of cases and controls. They found that a panel of genes (IL10, LCN2, ZAP70, AIM2, and TAL1) might be a diagnostic biomarker of pancreatic cancer.

In addition to methylation in specific genes, associations between global hypomethylation in peripheral blood leukocytes and cancer risk were reported for several cancers, including breast, bladder, colorectal adenoma, head and neck squamous cell carcinoma, tongue and esophageal cancer, and gastric cancer, as shown in Table 5.9,11,12,34,64,66–68 Some of these studies attempted to control for confounding factors in the association between methylation level and disease status by selecting subjects in certain cancer stages, as shown in a study of colorectal cancer,12 and by using stratified analysis of confounding factors, such as smoking status in a study of bladder cancer.11 Only 1 study investigated DNA methylation in peripheral blood leukocytes as a prognostic marker of cancer. Using pyrosequencing, Al-Moundhri et al found that global methylation and promoter methylation in p16 were associated with survival among 105 patients with gastric adenocarcinoma.68

4. CONCLUSION AND FUTURE DIRECTIONS

Because DNA methylation data are very complex and diverse, several points should be considered in study design and data analysis. For example, data could represent methylation content, methylation level, methylation pattern, methylation level profile, or methylation pattern profile.69 Second, the format of data might be discrete (qualitative measurement) or continuous (quantitative measurement), depending on the detection method. When continuous data are not normally distributed, they can be transformed or classified into groups for parametric analysis or, alternatively, tested by nonparametric analysis.70 However, methods of statistical analysis of methylation pattern and methylation profile have not been standardized, and the establishment of such techniques should be a topic of future studies.

A well-designed epidemiologic study is needed to evaluate the validity of a putative methylation-based biomarker. Strategies to validate biomarkers were well established in the community of the Early Detection Research Network (EDRN).71,72 The researchers developed a 5-phase strategy for identifying cancer biomarkers. These phases corresponded to 5 epidemiologic phases, as follows: (1) a preclinical exploratory phase in case-control studies with convenient samples, to identify promising directions; (2) a clinical assay and validation phase in population-based case-control studies, for validation in clinical settings; (3) a retrospective longitudinal phase in nested case-control studies, to determine whether the biomarker detects a disease before it becomes clinically significant; (4) a prospective screening phase in cross-sectional cohort studies, to identify the extent and characteristics of a disease and calculate the predictive value; and (5) a cancer control phase in randomized trials, to quantify the impact of screening on reducing the disease burden in the population. The standard operating procedures of each phase should include details of assays, methods, and protocols for collection and processing of biological samples and other reference materials. In addition, with regard to the characteristics of methylation, the timing of environmental exposure may be critical for altering methylation in disease progression; thus, specimen collection should be done in a prospective longitudinal study and should be done repeatedly.

More data must be collected to determine if blood-based DNA methylation is biologically plausible. In addition, a large prospective study is necessary to determine whether DNA methylation measured in peripheral blood is a useful and informative cancer biomarker.

ACKNOWLEDGMENTS

This work was supported by the Basic Science Research Program through the National Research Foundation of Korea, funded by the Ministry of Education, Science and Technology [2011-0027212], and by the National Research Foundation of Korea (NRF) A3 Foresight program.

Conflicts of interest: None declared.

REFERENCES

1. Wagner PD, Verma M, Srivastava S. Challenges for biomarkers in cancer detection. Ann N Y Acad Sci. 2004;1022:9–16.
2. Robertson KD. DNA methylation and human disease. Nat Rev Genet. 2005;6:597–610.
3. Wilson AS, Power BE, Molloy PL. DNA hypomethylation and human diseases. Biochim Biophys Acta. 2007;1775:138–62.
4. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet. 2007;8:286–98.
5. Shivapurkar N, Gazdar AF. DNA methylation based biomarkers in non-invasive cancer screening. Curr Mol Med. 2010;10:123–32.
6. Gormally E, Caboux E, Vineis P, Hainaut P. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res. 2007;635:105–17.
7. Gormally E, Hainaut P, Caboux E, Airoldi L, Atrup H, Malaveille C, et al. Amount of DNA in plasma and cancer risk: a prospective study. Int J Cancer. 2004;111:746–9.
8. Docherty SJ, Davis OS, Haworth CM, Plomin R, Mill J. DNA methylation profiling using bisulfite-based epityping of pooled

J Epidemiol 2012;22(5):384-394
genomic DNA. Methods. 2010;52:255–8.
9. Choi JY, James SR, Link PA, McCann SE, Hong CC, Davis W, et al. Association between global DNA hypomethylation in leukocytes and risk of breast cancer. Carcinogenesis. 2009;30: 1889–97.
10. Flanagan JM, Munoz-Alegre M, Henderson S, Tang T, Sun P, Johnson N, et al. Gene-body hypermethylation of ATM in peripheral blood DNA of bilateral breast cancer patients. Hum Mol Genet. 2009;18:1332–42.
11. Moore LE, Pfeiffer RM, Poscabco C, Real FX, Kogevinas M, Silverman D, et al. Genomic DNA hypomethylation as a biomarker for bladder cancer susceptibility in the Spanish Bladder Cancer Study: a case-control study. Lancet Oncol. 2008;9:359–66.
12. Lim U, Flood A, Choi SW, Albanes D, Cross AJ, Schatzkin A, et al. Dietary patterns are associated with levels of global DNA methylation in healthy volunteers. Gastroenterology. 2008;134:47–55.
13. Widschwendter M, Apostolidou S, Rauner M, Peter K, Ebert U, et al. Hypomethylation of p53 in peripheral blood DNA and breast cancer risk: a proof of principle study. PLoS ONE. 2008;3:e2656.
14. Ally MS, Al-Ghanim R, Purifoy M. The relationship between gene-specific DNA methylation in leukocytes and normal colorectal mucosa in subjects with and without colorectal tumors. Cancer Epidemiol Biomarkers Prev. 2009;18:922–8.
15. Woodson K, Mason J, Choi SW, Hartman T, Tangrea J, Virtamo J, et al. Hypomethylation of p53 in peripheral blood DNA is associated with the development of lung cancer. Cancer Epidemiol Biomarkers Prev. 2001;10:69–74.
16. Teschendorff AE, Menon U, Gentry-Maharaj A, Ramsay SJ, Gayther SA, Apostolidou S, et al. An epigenetic signature in peripheral blood predicts ovarian cancer risk. PLoS ONE. 2009;4:e8274.
17. Pedersen KS, Bamlert WR, Oberg AL, de Andrade M, Matsumoto ME, Tang H, et al. Leukocyte DNA methylation signature differentiates pancreatic cancer patients from healthy controls. PLoS ONE. 2011;6:e18223.
18. Kristensen LS, Hansen LL. PCR-based methods for detecting single-locus DNA methylation biomarkers in cancer diagnostics, prognostics, and response to treatment. Clin Chem. 2009;55: 1471–83.
19. Bibikova M, Fan JB. Genome-wide DNA methylation profiling. Wiley Interdiscip Rev Syst Biol Med. 2010;2:210–23.
20. Gupta R, Nagarajan A, Wajapeeyee N. Advances in genome-wide DNA methylation analysis. Biotechniques. 2010;49:iii–xi.
21. Bock C, Tomazou EM, Brinkman AB, Müller F, Simmer F, Gu H, et al. Quantitative comparison of genome-wide DNA methylation mapping technologies. Nat Biotechnol. 2010;28: 1106–14.
22. Bibikova M, Le J, Barnes B, Saedinia-Melynky S, Zhou L, Shen R, et al. Genome-wide DNA methylation profiling using Infinium assay. Epigenomics. 2009;1:177–200.
23. Catania J, Keenan BC, Margison GP, Fairweather DS. Determination of 5-methylcytosine by acid hydrolysis of DNA with hydrofluoric acid. Anal Biochem. 1987;167:347–51.
24. Song L, James SR, Kazim L, Karpf AR. Specific method for the determination of genomic DNA methylation by liquid chro-
breast cancer diagnosis in the Breast Cancer Family Registry. Cancer Epidemiol Biomarkers Prev. 2009;18:2723–5.

41. Wang YC, Yu ZH, Liu C, Xu LZ, Yu W, Lu J, et al. Detection of RASSF1A promoter hypermethylation in serum from gastric and colorectal adenocarcinoma patients. World J Gastroenterol. 2008;14:3074–80.

42. Müller HM, Fiegl H, Widschwendter A, Widschwendter M. Prognostic DNA methylation marker in serum of cancer patients. Ann N Y Acad Sci. 2004;1022:44–9.

43. Valenzuela MT, Galisteo R, Zuluaga A, Villalobos M, Náñez ML, Oliver FJ, et al. Assessing the use of p16INK4a promoter gene methylation in serum for detection of bladder cancer. Eur Urol. 2002;42:622–8, discussion 628–30.

44. Reibenwein J, Pils D, Horak P, Tomicek B, Goldner G, Worel N, et al. Promoter hypermethylation of GSTP1, AR, and 14-3-3sigma in serum of prostate cancer patients and its clinical relevance. Prostate. 2007;67:427–32.

45. Ellinger J, Haan K, Heukamp LC, Kahl P, Büttner R, Müller SC, et al. CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer. Prostate. 2008;68:42–9.

46. Wong TS, Man MW, Lam AK, Wei WI, Kwong YL, Yuen AP. The study of p16 and p15 gene methylation in head and neck squamous cell carcinoma and their quantitative evaluation in plasma by real-time PCR. Eur J Cancer. 2003;39:1881–7.

47. Fujiwara K, Fujimoto N, Tabata M, Nishii K, Matsuo K, Hotta K, et al. Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin Cancer Res. 2005;11:1219–25.

48. Lofton-Day C, Model F, Devos T, Tetzner R, Distler J, Schuster M, et al. DNA methylation biomarkers for blood-based colorectal cancer screening. Clin Chem. 2008;54:414–23.

49. Epigenomics AG. Epigenomics. 2011. http://www.epigenomics.com.

50. Zhang YJ, Wu HC, Shen J, Ahsan H, Tsai WY, Yang HI, et al. Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA. Clin Cancer Res. 2007;13:2378–84.

51. Göbel G, Auer D, Gaugg I, Schneitter A, Lesche R, Müller-Holzner E, et al. Prognostic significance of methylated RASSF1A and PITX2 genes in blood- and bone marrow plasma of breast cancer patients. Breast Cancer Res Treat. 2011;130:1:109–17.

52. Dominguez G, Carballido J, Silva J, Silva JM, García JM, Menéndez J, et al. p14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients. Clin Cancer Res. 2002;8:980–5.

53. Widschwendter A, Ivarsson L, Blassnig A, Müller HM, Fiegl H, Wiedemair A, et al. CDH1 and CDH13 methylation in serum is an independent prognostic marker in cervical cancer patients. Int J Cancer. 2004;109:163–6.

54. Wallner M, Herbst A, Behrens A, Crispin A, Stieber P, Göke B, et al. Methylation of serum DNA is an independent prognostic marker in colorectal cancer. Clin Cancer Res. 2006;12:7347–52.

55. Fiegl H, Millinger S, Mueller-Holzner E, Marth C, Ensinger C, Berger A, et al. Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res. 2005;65:1141–5.

56. Leung WK, To KF, Chu ES, Chan MW, Bai AH, Ng Ek, et al. Potential diagnostic and prognostic values of detecting promoter hypermethylation in the serum of patients with gastric cancer. Br J Cancer. 2005;92:2190–4.

57. Kawakami K, Brabender J, Lord RV, Groshen S, Greenwald BD, Krasna MJ, et al. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst. 2000;92:1805–11.

58. Widschwendter A, Müller HM, Fiegl H, Ivarsson L, Wiedemair A, Müller-Holzner E, et al. DNA methylation in serum and tumors of cervical cancer patients. Clin Cancer Res. 2004;10:565–71.

59. Gifford G, Paul J, Vasey PA, Kaye SB, Brown R. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res. 2004;10:4420–6.

60. Bastian PJ, Palapattu GS, Lin X, Yegnasubramanian S, Mangold LA, Trock B, et al. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res. 2005;11:4037–43.

61. Sunami E, Shinozaki M, Higano CS, Wollman R, Dorff TB, Tucker SJ, et al. Multimarker circulating DNA assay for assessing blood of prostate cancer patients. Clin Chem. 2009;55:559–67.

62. Lee BB, Lee EJ, Jung EH, Chun HK, Chang DK, Song SY, et al. Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer. Clin Cancer Res. 2009;15:6185–91.

63. Kaaks R, Stattin P, Villar S, Poetsch AR, Dossus L, Nieters A, et al. Insulin-like growth factor-II methylation status in lymphocyte DNA and colon cancer risk in the Northern Sweden Health and Disease cohort. Cancer Res. 2009;69:5400–5.

64. Cash HL, Tao L, Yuan JM, Marsit CJ, Houseman EA, Xiang YB, et al. LINE-1 hypomethylation is associated with bladder cancer risk among non-smoking Chinese. Int J Cancer. 2012;130(5):1151–9.

65. Wang L, Aakre JA, Jiang R, Marks RS, Wu Y, Chen J, et al. Assessing the use of p16INK4a promoter DNA: a marker for monitoring efficacies of adjuvant therapy in cancer patients. J Epidemiol. 2012;22(5):384-394
http://edrn.nci.nih.gov/.

72. Kagan J, Srivastava S, Barker PE, Belinsky SA, Cairns P. Towards Clinical Application of Methylated DNA Sequences as Cancer Biomarkers: A Joint NCI's EDRN and NIST Workshop on Standards, Methods, Assays, Reagents and Tools. Cancer Res. 2007;67:4545–9.

73. Hudson JJ, Pope HG Jr, Glynn RJ. The cross-sectional cohort study: an underutilized design. Epidemiology. 2005;16:355–9.

74. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996;93:9821–6.

75. Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci U S A. 1992;89:1827–31.

76. Dejeux E, Audard V, Cavard C, Gut IG, Terris B, Tost J. Rapid identification of promoter hypermethylation in hepatocellular carcinoma by pyrosequencing of etiologically homogeneous sample pools. J Mol Diagn. 2007;9:510–20.

77. Xiong Z, Laird PW. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res. 1997;25:2532–4.

78. Matsubayashi H, Sato N, Brune K, Blackford AL, Hruban RH, Canto M, et al. Age- and disease-related methylation of multiple genes in nonneoplastic duodenum and in duodenal juice. Clin Cancer Res. 2005;11:573–83.

79. Gonzalgo ML, Liang G. Methylation-sensitive single-nucleotide primer extension (Ms-SNuPE) for quantitative measurement of DNA methylation. Epigenetics Chromatin. 2010;3:12.

80. Tierling S, Schuster M, Tetzner R, Walter J. A combined HM-PCR/SNuPE method for high sensitive detection of rare DNA methylation. Genomics. 2007;9:1390–5.

81. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res. 2000;28:E32.

82. Bonanno C, Shehi E, Adlerstein D, Makrigiorgos GM. MS-FLAG, a novel real-time signal generation method for methylation-specific PCR. Clin Chem. 2007;53:2119–27.

83. Akama TO, Okazaki Y, Ito M, Okuizumi H, Konno H, Muramatsu M, et al. Restriction landmark genomic scanning (RLGS-M)-based genome-wide scanning of mouse liver tumors for alterations in DNA methylation status. Cancer Res. 1997;57:3294–9.

84. Ando Y, Hayashizaki Y. Restriction landmark genomic scanning. Nat Protoc. 2006;1(6):2774–83.

85. Huang TH, Laux DE, Hamlin BC, Tran P, Tran H, Lubahn DB. Identification of DNA methylation markers for human breast carcinomas using the methylation-sensitive restriction fingerprinting technique. Cancer Res. 1997;57:1030–4.

86. Weber M, Davies JJ, Wittig D, Oakeley EJ, Haase M, Lam WL, et al. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet. 2005;37:853–62.

87. Li M, Hu SL, Shen ZJ, He XD, Tao SN, Dong L, et al. High-performance capillary electrophoretic method for the quantification of global DNA methylation: application to methotrexate-resistant cells. Anal Biochem. 2009;387:71–5.

88. Radpour R, Barekat Z, Kohler C, Lv Q, Bürki N, Diesch C, et al. Hypermethylation of tumor suppressor genes involved in critical regulatory pathways for developing a blood-based test in breast cancer. PLoS ONE. 2011;6:e16080.

89. Wong TS, Kwong DL, Sham JS, Wei WI, Kwong YL, Yuen AP. Quantitative plasma hypermethylated DNA markers of undifferentiated nasopharyngeal carcinoma. Clin Cancer Res. 2004;10:2401–6.

90. Hoffmann AC, Kaif IT, Vallböhmer D, Yekebas E, Grimminger P, Leers JM, et al. Lack of prognostic significance of serum DNA methylation of DAPK, MGMT, and GSTPI in patients with non-small cell lung cancer. J Surg Oncol. 2009;100:414–7.

91. Ramirez JL, Rosell R, Taron M, Sanchez-Ronco M, Alberola V, de Las Peñas R, et al. 14-3-3{sigma} methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group. J Clin Oncol. 2005;23:9105–12.

92. Hoque MO, Feng Q, Toure P, Dem A, Critchlow CW, Hawes SE, et al. Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J Clin Oncol. 2006;24:4262–9.

93. deV os T, Tetzner R, Model F, Weiss G, Schuster M, Distler J, et al. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem. 2009;55:1337–46.

94. Melnikov AA, Scholtens D, Talamonti MS, Bentrem DJ, Levenson VV. Methylation profile of circulating plasma DNA in patients with pancreatic cancer. J Surg Oncol. 2009;99:119–22.

95. Cho YH, Yazici H, Wu HC, Terry MB, Gonzalez K, Qu M, et al. Aberrant promoter hypermethylation and genomic hypomethylation in tumor, adjacent normal tissues and blood from breast cancer patients. Anticancer Res. 2010;30:2489–96.

96. Wilhelm CS, Kelsey KT, Butler R, Plaza S, Gagne L, Zens MS, et al. Hypermethylation of tumor suppressor genes involved in critical regulatory pathways for developing a blood-based test in breast cancer. PLoS ONE. 2011;6:e16080.

97. Pinheiro H, Bordeira-Carriço R, Seixas S, Carvalho J, Senz J, Oliveira P, et al. Allele-specific CDH1 downregulation and hereditary diffuse gastric cancer. Hum Mol Genet. 2010;19:943–52.